Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.77 |
| ▸ | PGR | P06401 | 2/20 | 0.77 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | AR | P10275 | 1/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | SHBG | P04278 | 1/20 | 0.74 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone Phosphoric Acid SCHEMBL19475421 | 1.00 | HIF1A (0.77) | HIF1APGRSERPINA6LMNAAR | |
| Hydrocortisone Phosphoric Acid SCHEMBL250125 | 0.99 | HIF1A (0.78) | HIF1APGRSERPINA6LMNAAR | |
| Hydrocortisone Phosphoric Acid SCHEMBL7868481 | 0.99 | HIF1A (0.78) | HIF1APGRSERPINA6LMNAAR | |
| Hydrocortisone Phosphoric Acid SCHEMBL13026155 | 0.99 | HIF1A (0.78) | HIF1APGRSERPINA6LMNAAR | |
| Hydrocortisone Phosphoric Acid SCHEMBL31148432 | 0.98 | HIF1A (0.77) | HIF1APGRSERPINA6LMNAAR | |
| Hydrocortisone Phosphoric Acid SCHEMBL15475784 | 0.94 | HIF1A (0.71) | HIF1APGRSERPINA6LMNAAR | |
| SCHEMBL16170234 | 0.93 | HIF1A (0.77) | HIF1APGRSERPINA6LMNAAR | |
| Hydrocortisone Phosphoric Acid SCHEMBL21647387 | 0.92 | HIF1A (0.75) | HIF1APGRSERPINA6LMNAAR | |
| Hydrocortisone Phosphoric Acid SCHEMBL42271 | 0.91 | HIF1A (0.77) | HIF1APGRSERPINA6LMNAAR | |
| Hydrocortisone Phosphoric Acid SCHEMBL1761098 | 0.91 | HIF1A (0.77) | HIF1APGRSERPINA6LMNAAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118251209-A | Hydrocortisone pharmaceutical solution for injection device | 克鲁斯杰克特公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-113660952-B | Bispecific antibodies | 小野药品工业株式会社 | 2024-06-11 | — | — | CN | disclosed |
| US-20240130980-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | Ilera Derm LLC | 2024-04-25 | — | — | US | disclosed |
| CN-110785180-B | Oncolytic viral therapy and immunotherapy | 贝勒医学院 | 2024-04-02 | — | — | CN | disclosed |
| US-11931452-B2 | Topical compositions containing rofecoxib and methods of making and using the same | JF PHARMA TECH LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-11890260-B2 | Compositions for treating acne and dermatological conditions | Ilera Derm LLC (US) | 2024-02-06 | — | — | US | disclosed |
| CN-117500803-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-111670203-B | bispecific antibodies | 小野药品工业株式会社 | 2023-11-14 | — | — | CN | disclosed |
| CN-116327482-A | Apparatus and method for ocular injection | 科尼尔赛德生物医学公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116234548-A | Compounds comprising tricyclic parent nucleus as PD-1/PD-L1 blockers | 再生治疗有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-7300917-B2 | Remedy for chronic disease | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-11-27 | — | — | US | disclosed |
| EP-1852420-A1 | INDOLE COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20060194797-A1 | Condensed ring compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-20060135577-A1 | Remedy for chronic disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1661892-A1 | CONDENSED RING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-1550461-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1197209-A1 | PERCUTANEOUSLY ABSORBABLE PREPARATIONS | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-0953357-A1 | NEPHROTROPIC DRUGS | Drug Delivery System Institute, Ltd. (JP) | 1999-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11890260-B2 | Compositions for treating acne and dermatological conditions | COQ8A, ATP5ME, AGK | NR3C1 3071/4885HIF1A 1441/4885PGR 590/4885 |
| US-20060194797-A1 | Condensed ring compound and use thereof | CYSLTR2, CYSLTR1, LTB4R2 | NR3C1 117/4885HIF1A 1982/4885PGR 2013/4885 |
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | NR3C1 34/4885HIF1A 340/4885PGR 450/4885 |
| US-20060135577-A1 | Remedy for chronic disease | EDNRA, EDNRB, LPAR2 | NR3C1 159/4885HIF1A 3307/4885PGR 1452/4885 |
| US-20240130980-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | COQ8A, ATP5ME, AGK | NR3C1 3071/4885HIF1A 1441/4885PGR 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.